tiprankstipranks
Trending News
More News >

Solasia Pharma Reports Fiscal Results and Product Pipeline Updates

Story Highlights
Solasia Pharma Reports Fiscal Results and Product Pipeline Updates

Don’t Miss TipRanks’ Half-Year Sale

Solasia Pharma KK ( (JP:4597) ) just unveiled an announcement.

Solasia Pharma K.K. has reported its consolidated financial results for the fiscal year ending December 31, 2024, along with updates on its major pipeline products. Sancuso® faced a significant decline in sales in China due to shipment constraints after transferring its manufacturing facility. On the other hand, DARVIAS® Injection received marketing approval in Japan, with Nippon Kayaku handling its sales, and efforts are underway to seek regulatory approval in South America, where HB Human BioScience is involved.

More about Solasia Pharma KK

Solasia Pharma K.K. operates in the pharmaceutical industry, focusing on the development and commercialization of oncology and supportive care products. Its primary products include Sancuso®, a transdermal delivery system for chemotherapy-induced nausea and vomiting, and DARVIAS® Injection, an organic arsenic compound for the treatment of peripheral T-cell lymphoma. The company has a market focus in regions including China and Japan, and it collaborates with partners like Lee’s Pharmaceutical and Nippon Kayaku for product sales and distribution.

YTD Price Performance: 21.05%

Average Trading Volume: 304

Technical Sentiment Consensus Rating: Buy

Current Market Cap: €53.48M

See more data about 4597 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1